Anti-angiotensin II type 1 receptor autoantibodies (AT1R-AAs) in patients with systemic sclerosis: lack of association with disease manifestations

Angiotensin II type 1 receptor autoantibodies (AT 1 R-AAs) are known to be associated with malignant hypertension, preeclampsia, and vascular rejection in kidney transplantation. They were also suspected to have pathogenetic role in vasculopathic changes in systemic sclerosis (SSc). Clinical data re...

Full description

Saved in:
Bibliographic Details
Published inRheumatology international Vol. 37; no. 4; pp. 593 - 598
Main Authors İlgen, Ufuk, Yayla, Müçteba Enes, Düzgün, Nurşen
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer Berlin Heidelberg 01.04.2017
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Angiotensin II type 1 receptor autoantibodies (AT 1 R-AAs) are known to be associated with malignant hypertension, preeclampsia, and vascular rejection in kidney transplantation. They were also suspected to have pathogenetic role in vasculopathic changes in systemic sclerosis (SSc). Clinical data regarding AT 1 R-AAs in SSc are scarce. In this work, we will examine the relationship between serum levels of AT 1 R-AAs and disease manifestations. Serum samples from SSc patients and healthy controls were analyzed for AT 1 R-AAs by using a commercial ELISA kit. We examined the association of serum levels of AT 1 R-AA with disease duration, systolic pulmonary artery pressure (sPAP) measurements, and disease manifestations like cutaneous, lung and esophageal involvements, and the presence of digital ulcers in a cross-sectional manner. There was no statistically significant difference in levels of AT 1 R-AAs between SSc ( n  = 93) patients and healthy controls ( n  = 66) ( p  = 0.23). Serum levels of AT 1 R-AAs were not correlated with disease duration, sPAP measurements, and showed no association with disease manifestations like lung involvement, esophageal involvement, digital ulcers, and cutaneous fibrosis. In our SSc cohort, AT 1 R-AA serum levels were not different from healthy subjects and higher levels were not associated with any disease manifestation neither.
AbstractList Angiotensin II type 1 receptor autoantibodies (AT1R-AAs) are known to be associated with malignant hypertension, preeclampsia, and vascular rejection in kidney transplantation. They were also suspected to have pathogenetic role in vasculopathic changes in systemic sclerosis (SSc). Clinical data regarding AT1R-AAs in SSc are scarce. In this work, we will examine the relationship between serum levels of AT1R-AAs and disease manifestations. Serum samples from SSc patients and healthy controls were analyzed for AT1R-AAs by using a commercial ELISA kit. We examined the association of serum levels of AT1R-AA with disease duration, systolic pulmonary artery pressure (sPAP) measurements, and disease manifestations like cutaneous, lung and esophageal involvements, and the presence of digital ulcers in a cross-sectional manner. There was no statistically significant difference in levels of AT1R-AAs between SSc (n = 93) patients and healthy controls (n = 66) (p = 0.23). Serum levels of AT1R-AAs were not correlated with disease duration, sPAP measurements, and showed no association with disease manifestations like lung involvement, esophageal involvement, digital ulcers, and cutaneous fibrosis. In our SSc cohort, AT1R-AA serum levels were not different from healthy subjects and higher levels were not associated with any disease manifestation neither.Angiotensin II type 1 receptor autoantibodies (AT1R-AAs) are known to be associated with malignant hypertension, preeclampsia, and vascular rejection in kidney transplantation. They were also suspected to have pathogenetic role in vasculopathic changes in systemic sclerosis (SSc). Clinical data regarding AT1R-AAs in SSc are scarce. In this work, we will examine the relationship between serum levels of AT1R-AAs and disease manifestations. Serum samples from SSc patients and healthy controls were analyzed for AT1R-AAs by using a commercial ELISA kit. We examined the association of serum levels of AT1R-AA with disease duration, systolic pulmonary artery pressure (sPAP) measurements, and disease manifestations like cutaneous, lung and esophageal involvements, and the presence of digital ulcers in a cross-sectional manner. There was no statistically significant difference in levels of AT1R-AAs between SSc (n = 93) patients and healthy controls (n = 66) (p = 0.23). Serum levels of AT1R-AAs were not correlated with disease duration, sPAP measurements, and showed no association with disease manifestations like lung involvement, esophageal involvement, digital ulcers, and cutaneous fibrosis. In our SSc cohort, AT1R-AA serum levels were not different from healthy subjects and higher levels were not associated with any disease manifestation neither.
Angiotensin II type 1 receptor autoantibodies (AT 1 R-AAs) are known to be associated with malignant hypertension, preeclampsia, and vascular rejection in kidney transplantation. They were also suspected to have pathogenetic role in vasculopathic changes in systemic sclerosis (SSc). Clinical data regarding AT 1 R-AAs in SSc are scarce. In this work, we will examine the relationship between serum levels of AT 1 R-AAs and disease manifestations. Serum samples from SSc patients and healthy controls were analyzed for AT 1 R-AAs by using a commercial ELISA kit. We examined the association of serum levels of AT 1 R-AA with disease duration, systolic pulmonary artery pressure (sPAP) measurements, and disease manifestations like cutaneous, lung and esophageal involvements, and the presence of digital ulcers in a cross-sectional manner. There was no statistically significant difference in levels of AT 1 R-AAs between SSc ( n  = 93) patients and healthy controls ( n  = 66) ( p  = 0.23). Serum levels of AT 1 R-AAs were not correlated with disease duration, sPAP measurements, and showed no association with disease manifestations like lung involvement, esophageal involvement, digital ulcers, and cutaneous fibrosis. In our SSc cohort, AT 1 R-AA serum levels were not different from healthy subjects and higher levels were not associated with any disease manifestation neither.
Angiotensin II type 1 receptor autoantibodies (AT R-AAs) are known to be associated with malignant hypertension, preeclampsia, and vascular rejection in kidney transplantation. They were also suspected to have pathogenetic role in vasculopathic changes in systemic sclerosis (SSc). Clinical data regarding AT R-AAs in SSc are scarce. In this work, we will examine the relationship between serum levels of AT R-AAs and disease manifestations. Serum samples from SSc patients and healthy controls were analyzed for AT R-AAs by using a commercial ELISA kit. We examined the association of serum levels of AT R-AA with disease duration, systolic pulmonary artery pressure (sPAP) measurements, and disease manifestations like cutaneous, lung and esophageal involvements, and the presence of digital ulcers in a cross-sectional manner. There was no statistically significant difference in levels of AT R-AAs between SSc (n = 93) patients and healthy controls (n = 66) (p = 0.23). Serum levels of AT R-AAs were not correlated with disease duration, sPAP measurements, and showed no association with disease manifestations like lung involvement, esophageal involvement, digital ulcers, and cutaneous fibrosis. In our SSc cohort, AT R-AA serum levels were not different from healthy subjects and higher levels were not associated with any disease manifestation neither.
Angiotensin II type 1 receptor autoantibodies (AT1R-AAs) are known to be associated with malignant hypertension, preeclampsia, and vascular rejection in kidney transplantation. They were also suspected to have pathogenetic role in vasculopathic changes in systemic sclerosis (SSc). Clinical data regarding AT 1R-AAs in SSc are scarce. In this work, we will examine the relationship between serum levels of AT1R-AAs and disease manifestations. Serum samples from SSc patients and healthy controls were analyzed for AT1R-AAs by using a commercial ELISA kit. We examined the association of serum levels of AT1R-AA with disease duration, systolic pulmonary artery pressure (sPAP) measurements, and disease manifestations like cutaneous, lung and esophageal involvements, and the presence of digital ulcers in a cross-sectional manner. There was no statistically significant difference in levels of AT 1R-AAs between SSc (n = 93) patients and healthy controls (n = 66) (p = 0.23). Serum levels of AT1R-AAs were not correlated with disease duration, sPAP measurements, and showed no association with disease manifestations like lung involvement, esophageal involvement, digital ulcers, and cutaneous fibrosis. In our SSc cohort, AT1R-AA serum levels were not different from healthy subjects and higher levels were not associated with any disease manifestation neither.
Author İlgen, Ufuk
Düzgün, Nurşen
Yayla, Müçteba Enes
Author_xml – sequence: 1
  givenname: Ufuk
  orcidid: 0000-0001-6443-6426
  surname: İlgen
  fullname: İlgen, Ufuk
  email: ufukilgen@gmail.com
  organization: Department of Internal Medicine, İbn-i Sina Hospital, Ankara University Medical School
– sequence: 2
  givenname: Müçteba Enes
  surname: Yayla
  fullname: Yayla, Müçteba Enes
  organization: Department of Internal Medicine, İbn-i Sina Hospital, Ankara University Medical School
– sequence: 3
  givenname: Nurşen
  surname: Düzgün
  fullname: Düzgün, Nurşen
  organization: Department of Rheumatology, Ankara University Medical School
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28004166$$D View this record in MEDLINE/PubMed
BookMark eNp9kVFr1TAYhoNM3NnRH-CNBLzZLqpJ2ian3pWh88BAkAnehTT9MjPbpPZLkfM3_MXm2A1koDcJIc_75s33npGTEAMQ8pKzN5wx9RYZE40sGJdFKcumqJ6QDa9KVXDJvp6QDeNKFLu8nJIzxDuWz1KyZ-RU7BiruJQb8qsNyRcm3PqYIKAPdL-n6TAB5XQGC1OKMzVLiiZzXew9ID1vb_jnom3xgmZ-MslDSEh_-vSN4gETjN5StAPMET2-o4Ox32l01CBG6zMewwr3HsEg0NEE7wDTnyt8Tp46MyC8uN-35MuH9zeXH4vrT1f7y_a6sKUSqRC7quK9q13FQXR1I6rSdp1qVN3zXlQdV84a0SjhpOh7AKuYdCVTvHROVs6UW3K--k5z_LHk5_Xo0cIwmABxQc13NZdNJbLxlrx-hN7FZQ45XaZUU0rBZJ2pV_fU0o3Q62n2o5kP-mHaGVArYPNkcAanrV8_nWbjB82ZPvaq11517lUfe9XHAPyR8sH8fxqxajCz4Rbmv0L_U_QbvDy1fg
CitedBy_id crossref_primary_10_3389_fimmu_2022_1045523
crossref_primary_10_1016_j_autrev_2018_06_009
crossref_primary_10_1002_art_43099
crossref_primary_10_1097_BOR_0000000000000550
crossref_primary_10_3389_fimmu_2021_786039
crossref_primary_10_1016_j_humimm_2019_04_007
Cites_doi 10.1016/j.transproceed.2014.11.055
10.1111/ajt.12395
10.1097/00004872-200018070-00017
10.1586/eci.11.56
10.1002/art.38098
10.1056/NEJMoa035717
10.1111/tri.12371
10.1016/j.jcf.2014.07.007
10.1136/ard.2010.135772
10.1186/ar4457
10.1097/TP.0b013e3181fd97f1
10.1097/TP.0000000000000182
10.1164/rccm.201403-0442OC
10.1111/nep.12441
10.1097/TP.0000000000000185
10.1016/j.transproceed.2014.09.029
10.1093/ndt/gfv375
10.4049/jimmunol.138.4.1164
ContentType Journal Article
Copyright Springer-Verlag Berlin Heidelberg 2016
Rheumatology International is a copyright of Springer, 2017.
Copyright_xml – notice: Springer-Verlag Berlin Heidelberg 2016
– notice: Rheumatology International is a copyright of Springer, 2017.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8AO
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1007/s00296-016-3639-4
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Medical Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Pharma Collection
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
ProQuest Health & Medical Research Collection
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
ProQuest One Academic Middle East (New)
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1437-160X
EndPage 598
ExternalDocumentID 4321033171
28004166
10_1007_s00296_016_3639_4
Genre Journal Article
GrantInformation_xml – fundername: Ankara Tıplılar Vakfı
GroupedDBID ---
-53
-5E
-5G
-BR
-EM
-Y2
-~C
.86
.GJ
.VR
06C
06D
0R~
0VY
123
199
1N0
1SB
2.D
203
28-
29P
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
36B
3V.
4.4
406
408
409
40D
40E
53G
5QI
5RE
5VS
67Z
6NX
78A
7X7
88E
8AO
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABKTR
ABMNI
ABMQK
ABNWP
ABPLI
ABQSL
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFS
ACHSB
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACUDM
ACZOJ
ADBBV
ADHHG
ADHIR
ADIMF
ADINQ
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFEXP
AFKRA
AFLOW
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
B-.
BA0
BBWZM
BDATZ
BENPR
BGNMA
BPHCQ
BSONS
BVXVI
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
DU5
EBD
EBLON
EBS
EIOEI
EJD
EMB
EMOBN
EN4
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GQ8
GRRUI
GXS
H13
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I09
IHE
IJ-
IKXTQ
IMOTQ
IWAJR
IXC
IXD
IXE
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KOW
KPH
L7B
LAS
LLZTM
M1P
M4Y
MA-
N2Q
N9A
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
P19
P9S
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R4E
R89
R9I
RHV
RIG
RNI
RNS
ROL
RPX
RRX
RSV
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SCLPG
SDE
SDH
SDM
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK8
YLTOR
Z45
Z7U
Z82
Z83
Z87
Z8O
Z8V
Z8W
Z91
ZGI
ZMTXR
ZOVNA
~A9
~EX
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ACSTC
ADHKG
AEZWR
AFDZB
AFHIU
AFOHR
AGQPQ
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
7XB
8FK
ABRTQ
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
ID FETCH-LOGICAL-c372t-28441df5f41e2b59243cbb7975d1d24b17fca2972f62ddeec706f30713ff64fa3
IEDL.DBID 7X7
ISSN 0172-8172
1437-160X
IngestDate Fri Jul 11 03:46:01 EDT 2025
Fri Jul 25 10:28:35 EDT 2025
Wed Feb 19 02:00:17 EST 2025
Thu Apr 24 23:12:06 EDT 2025
Tue Jul 01 03:38:04 EDT 2025
Fri Feb 21 02:39:59 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords R
Digital ulceration
Pulmonary arterial hypertension
AT
Angiotensin II type 1 receptor antibodies
Systemic sclerosis
AT1R
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c372t-28441df5f41e2b59243cbb7975d1d24b17fca2972f62ddeec706f30713ff64fa3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-6443-6426
PMID 28004166
PQID 1879362065
PQPubID 326313
PageCount 6
ParticipantIDs proquest_miscellaneous_1851694224
proquest_journals_1879362065
pubmed_primary_28004166
crossref_citationtrail_10_1007_s00296_016_3639_4
crossref_primary_10_1007_s00296_016_3639_4
springer_journals_10_1007_s00296_016_3639_4
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20170400
2017-4-00
2017-Apr
20170401
PublicationDateYYYYMMDD 2017-04-01
PublicationDate_xml – month: 4
  year: 2017
  text: 20170400
PublicationDecade 2010
PublicationPlace Berlin/Heidelberg
PublicationPlace_xml – name: Berlin/Heidelberg
– name: Germany
– name: Heidelberg
PublicationSubtitle Clinical and Experimental Investigations
PublicationTitle Rheumatology international
PublicationTitleAbbrev Rheumatol Int
PublicationTitleAlternate Rheumatol Int
PublicationYear 2017
Publisher Springer Berlin Heidelberg
Springer Nature B.V
Publisher_xml – name: Springer Berlin Heidelberg
– name: Springer Nature B.V
References Couraud (CR1) 1987; 138
Ohe, Uchida, Yoshizawa, Hirao, Taniguchi, Maruya, Yurugi, Hishida, Maekawa, Uemoto (CR12) 2014; 98
LeRoy, Black, Fleischmajer, Jablonska, Krieg, Medsger, Rowell, Wollheim (CR19) 1988; 15
Budding, van de Graaf, Hoefnagel, Kwakkel-van Erp, van Kessel, Dragun, Hack, Otten (CR14) 2015; 14
Chiron, Bouaziz, Carmagnat, Peffault de Latour, Lafaurie-Bergeron, Robin, Xhaard, Toubert, Charron, Guigue (CR13) 2014; 98
Dragun, Muller, Brasen, Fritsche, Nieminen-Kelha, Dechend, Kintscher, Rudolph, Hoebeke, Eckert (CR4) 2005; 352
Fuss, Hope, Deayton, Bennett, Holdsworth, Carroll, Coates (CR7) 2015; 20
Banasik, Boratynska, Koscielska-Kasprzak, Kaminska, Bartoszek, Zabinska, Myszka, Zmonarski, Protasiewicz, Nowakowska (CR5) 2014; 27
Taniguchi, Rebellato, Cai, Hopfield, Briley, Haisch, Catrou, Bolin, Parker, Kendrick (CR10) 2013; 13
Reinsmoen, Lai, Heidecke, Haas, Cao, Ong, Naim, Wang, Mirocha, Kahwaji (CR11) 2010; 90
Becker, Kill, Kutsche, Guenther, Rose, Tabeling, Witzenrath, Kuhl, Heidecke, Ghofrani (CR15) 2014; 190
Fu, Herlitz, Schulze, Wallukat, Micke, Eftekhari, Sjogren, Hjalmarson, Muller-Esterl, Hoebeke (CR2) 2000; 18
van den Hoogen, Khanna, Fransen, Johnson, Baron, Tyndall, Matucci-Cerinic, Naden, Medsger (CR18) 2013; 65
Xia, Kellems (CR3) 2011; 7
Lee, Park, Kim, Lee, Kim, Kim, Huh (CR9) 2015; 47
Kill, Tabeling, Undeutsch, Kuhl, Gunther, Radic, Becker, Heidecke, Worm, Witzenrath (CR17) 2014; 16
Banasik, Boratynska, Koscielska-Kasprzak, Kaminska, Zmonarski, Mazanowska, Krajewska, Bartoszek, Zabinska, Myszka (CR6) 2014; 46
Lee, Huh, Park, Park, Yang, Jeong, Lee, Park, Cho, Lee (CR8) 2015
Riemekasten, Philippe, Nather, Slowinski, Muller, Heidecke, Matucci-Cerinic, Czirjak, Lukitsch, Becker (CR16) 2011; 70
H Ohe (3639_CR12) 2014; 98
M Taniguchi (3639_CR10) 2013; 13
NL Reinsmoen (3639_CR11) 2010; 90
Y Xia (3639_CR3) 2011; 7
EC LeRoy (3639_CR19) 1988; 15
M Banasik (3639_CR6) 2014; 46
F Hoogen van den (3639_CR18) 2013; 65
A Chiron (3639_CR13) 2014; 98
D Dragun (3639_CR4) 2005; 352
J Lee (3639_CR8) 2015
G Riemekasten (3639_CR16) 2011; 70
M Banasik (3639_CR5) 2014; 27
J Lee (3639_CR9) 2015; 47
A Kill (3639_CR17) 2014; 16
ML Fu (3639_CR2) 2000; 18
A Fuss (3639_CR7) 2015; 20
MO Becker (3639_CR15) 2014; 190
PO Couraud (3639_CR1) 1987; 138
K Budding (3639_CR14) 2015; 14
23941128 - Am J Transplant. 2013 Oct;13(10):2577-89
21895478 - Expert Rev Clin Immunol. 2011 Sep;7(5):659-74
24873781 - Transplantation. 2014 Aug 27;98(4):470-4
26546592 - Nephrol Dial Transplant. 2017 Jul 1;32(7):1244-1250
24472528 - Arthritis Res Ther. 2014 Jan 28;16(1):R29
15703421 - N Engl J Med. 2005 Feb 10;352(6):558-69
24909812 - Transpl Int. 2014 Oct;27(10):1029-38
24122180 - Arthritis Rheum. 2013 Nov;65(11):2737-47
2433343 - J Immunol. 1987 Feb 15;138(4):1164-8
25891704 - Transplant Proc. 2015 Apr;47(3):649-52
10930193 - J Hypertens. 2000 Jul;18(7):945-53
25096855 - J Cyst Fibros. 2015 Jan;14(1):42-5
25726938 - Nephrology (Carlton). 2015 Jul;20(7):467-73
21030904 - Transplantation. 2010 Dec 27;90(12):1473-7
25181620 - Am J Respir Crit Care Med. 2014 Oct 1;190(7):808-17
21081526 - Ann Rheum Dis. 2011 Mar;70(3):530-6
3361530 - J Rheumatol. 1988 Feb;15(2):202-5
25380879 - Transplant Proc. 2014 Oct;46(8):2618-21
24914568 - Transplantation. 2014 Nov 27;98(10):1105-11
References_xml – year: 2015
  ident: CR8
  article-title: The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation
  publication-title: Nephrol Dial Transpl
– volume: 47
  start-page: 649
  issue: 3
  year: 2015
  end-page: 652
  ident: CR9
  article-title: Clinical implications of angiotensin II type 1 receptor antibodies in antibody-mediated rejection without detectable donor-specific HLA antibodies after renal transplantation
  publication-title: Transplant Proc
  doi: 10.1016/j.transproceed.2014.11.055
– volume: 13
  start-page: 2577
  issue: 10
  year: 2013
  end-page: 2589
  ident: CR10
  article-title: Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies
  publication-title: Am J Transplant
  doi: 10.1111/ajt.12395
– volume: 18
  start-page: 945
  issue: 7
  year: 2000
  end-page: 953
  ident: CR2
  article-title: Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension
  publication-title: J Hypertens
  doi: 10.1097/00004872-200018070-00017
– volume: 7
  start-page: 659
  issue: 5
  year: 2011
  end-page: 674
  ident: CR3
  article-title: Receptor-activating autoantibodies and disease: preeclampsia and beyond
  publication-title: Expert Rev Clin Immunol
  doi: 10.1586/eci.11.56
– volume: 65
  start-page: 2737
  issue: 11
  year: 2013
  end-page: 2747
  ident: CR18
  article-title: 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative
  publication-title: Arthritis Rheum
  doi: 10.1002/art.38098
– volume: 352
  start-page: 558
  issue: 6
  year: 2005
  end-page: 569
  ident: CR4
  article-title: Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa035717
– volume: 27
  start-page: 1029
  issue: 10
  year: 2014
  end-page: 1038
  ident: CR5
  article-title: The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes
  publication-title: Transpl Int
  doi: 10.1111/tri.12371
– volume: 14
  start-page: 42
  issue: 1
  year: 2015
  end-page: 45
  ident: CR14
  article-title: Anti-ETAR and anti-AT1R autoantibodies are elevated in patients with endstage cystic fibrosis
  publication-title: J Cyst Fibros
  doi: 10.1016/j.jcf.2014.07.007
– volume: 70
  start-page: 530
  issue: 3
  year: 2011
  end-page: 536
  ident: CR16
  article-title: Involvement of functional autoantibodies against vascular receptors in systemic sclerosis
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2010.135772
– volume: 16
  start-page: R29
  issue: 1
  year: 2014
  ident: CR17
  article-title: Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis
  publication-title: Arthritis Res Ther
  doi: 10.1186/ar4457
– volume: 138
  start-page: 1164
  issue: 4
  year: 1987
  end-page: 1168
  ident: CR1
  article-title: Anti-angiotensin II anti-idiotypic antibodies bind to angiotensin II receptor
  publication-title: J Immunol
– volume: 90
  start-page: 1473
  issue: 12
  year: 2010
  end-page: 1477
  ident: CR11
  article-title: Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients
  publication-title: Transplantation
  doi: 10.1097/TP.0b013e3181fd97f1
– volume: 98
  start-page: 470
  issue: 4
  year: 2014
  end-page: 474
  ident: CR13
  article-title: Anti-Angiotensin type 1 receptor antibodies in chronic graft-versus-host disease
  publication-title: Transplantation
  doi: 10.1097/TP.0000000000000182
– volume: 15
  start-page: 202
  issue: 2
  year: 1988
  end-page: 205
  ident: CR19
  article-title: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis
  publication-title: J Rheumatol
– volume: 190
  start-page: 808
  issue: 7
  year: 2014
  end-page: 817
  ident: CR15
  article-title: Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.201403-0442OC
– volume: 20
  start-page: 467
  issue: 7
  year: 2015
  end-page: 473
  ident: CR7
  article-title: C4d-negative antibody-mediated rejection with high anti-angiotensin II type I receptor antibodies in absence of donor-specific antibodies
  publication-title: Nephrol (Carlton)
  doi: 10.1111/nep.12441
– volume: 98
  start-page: 1105
  issue: 10
  year: 2014
  end-page: 1111
  ident: CR12
  article-title: Association of anti-human leukocyte antigen and anti-angiotensin II type 1 receptor antibodies with liver allograft fibrosis after immunosuppression withdrawal
  publication-title: Transplantation
  doi: 10.1097/TP.0000000000000185
– volume: 46
  start-page: 2618
  issue: 8
  year: 2014
  end-page: 2621
  ident: CR6
  article-title: Non-HLA antibodies: angiotensin II type 1 receptor (anti-AT1R) and endothelin-1 type A receptor (anti-ETAR) are associated with renal allograft injury and graft loss
  publication-title: Transplant Proc
  doi: 10.1016/j.transproceed.2014.09.029
– volume: 20
  start-page: 467
  issue: 7
  year: 2015
  ident: 3639_CR7
  publication-title: Nephrol (Carlton)
  doi: 10.1111/nep.12441
– volume: 98
  start-page: 1105
  issue: 10
  year: 2014
  ident: 3639_CR12
  publication-title: Transplantation
  doi: 10.1097/TP.0000000000000185
– volume: 47
  start-page: 649
  issue: 3
  year: 2015
  ident: 3639_CR9
  publication-title: Transplant Proc
  doi: 10.1016/j.transproceed.2014.11.055
– volume: 14
  start-page: 42
  issue: 1
  year: 2015
  ident: 3639_CR14
  publication-title: J Cyst Fibros
  doi: 10.1016/j.jcf.2014.07.007
– volume: 16
  start-page: R29
  issue: 1
  year: 2014
  ident: 3639_CR17
  publication-title: Arthritis Res Ther
  doi: 10.1186/ar4457
– volume: 65
  start-page: 2737
  issue: 11
  year: 2013
  ident: 3639_CR18
  publication-title: Arthritis Rheum
  doi: 10.1002/art.38098
– volume: 90
  start-page: 1473
  issue: 12
  year: 2010
  ident: 3639_CR11
  publication-title: Transplantation
  doi: 10.1097/TP.0b013e3181fd97f1
– volume: 27
  start-page: 1029
  issue: 10
  year: 2014
  ident: 3639_CR5
  publication-title: Transpl Int
  doi: 10.1111/tri.12371
– volume: 46
  start-page: 2618
  issue: 8
  year: 2014
  ident: 3639_CR6
  publication-title: Transplant Proc
  doi: 10.1016/j.transproceed.2014.09.029
– volume: 352
  start-page: 558
  issue: 6
  year: 2005
  ident: 3639_CR4
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa035717
– year: 2015
  ident: 3639_CR8
  publication-title: Nephrol Dial Transpl
  doi: 10.1093/ndt/gfv375
– volume: 13
  start-page: 2577
  issue: 10
  year: 2013
  ident: 3639_CR10
  publication-title: Am J Transplant
  doi: 10.1111/ajt.12395
– volume: 98
  start-page: 470
  issue: 4
  year: 2014
  ident: 3639_CR13
  publication-title: Transplantation
  doi: 10.1097/TP.0000000000000182
– volume: 15
  start-page: 202
  issue: 2
  year: 1988
  ident: 3639_CR19
  publication-title: J Rheumatol
– volume: 138
  start-page: 1164
  issue: 4
  year: 1987
  ident: 3639_CR1
  publication-title: J Immunol
  doi: 10.4049/jimmunol.138.4.1164
– volume: 7
  start-page: 659
  issue: 5
  year: 2011
  ident: 3639_CR3
  publication-title: Expert Rev Clin Immunol
  doi: 10.1586/eci.11.56
– volume: 190
  start-page: 808
  issue: 7
  year: 2014
  ident: 3639_CR15
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.201403-0442OC
– volume: 70
  start-page: 530
  issue: 3
  year: 2011
  ident: 3639_CR16
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.2010.135772
– volume: 18
  start-page: 945
  issue: 7
  year: 2000
  ident: 3639_CR2
  publication-title: J Hypertens
  doi: 10.1097/00004872-200018070-00017
– reference: 24472528 - Arthritis Res Ther. 2014 Jan 28;16(1):R29
– reference: 21030904 - Transplantation. 2010 Dec 27;90(12):1473-7
– reference: 24909812 - Transpl Int. 2014 Oct;27(10):1029-38
– reference: 23941128 - Am J Transplant. 2013 Oct;13(10):2577-89
– reference: 26546592 - Nephrol Dial Transplant. 2017 Jul 1;32(7):1244-1250
– reference: 25891704 - Transplant Proc. 2015 Apr;47(3):649-52
– reference: 25380879 - Transplant Proc. 2014 Oct;46(8):2618-21
– reference: 10930193 - J Hypertens. 2000 Jul;18(7):945-53
– reference: 24873781 - Transplantation. 2014 Aug 27;98(4):470-4
– reference: 3361530 - J Rheumatol. 1988 Feb;15(2):202-5
– reference: 2433343 - J Immunol. 1987 Feb 15;138(4):1164-8
– reference: 25726938 - Nephrology (Carlton). 2015 Jul;20(7):467-73
– reference: 21081526 - Ann Rheum Dis. 2011 Mar;70(3):530-6
– reference: 25181620 - Am J Respir Crit Care Med. 2014 Oct 1;190(7):808-17
– reference: 24914568 - Transplantation. 2014 Nov 27;98(10):1105-11
– reference: 15703421 - N Engl J Med. 2005 Feb 10;352(6):558-69
– reference: 24122180 - Arthritis Rheum. 2013 Nov;65(11):2737-47
– reference: 25096855 - J Cyst Fibros. 2015 Jan;14(1):42-5
– reference: 21895478 - Expert Rev Clin Immunol. 2011 Sep;7(5):659-74
SSID ssj0017660
Score 2.1605663
Snippet Angiotensin II type 1 receptor autoantibodies (AT 1 R-AAs) are known to be associated with malignant hypertension, preeclampsia, and vascular rejection in...
Angiotensin II type 1 receptor autoantibodies (AT R-AAs) are known to be associated with malignant hypertension, preeclampsia, and vascular rejection in kidney...
Angiotensin II type 1 receptor autoantibodies (AT1R-AAs) are known to be associated with malignant hypertension, preeclampsia, and vascular rejection in kidney...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 593
SubjectTerms Adult
Aged
Autoantibodies - blood
Biomarkers
Cross-Sectional Studies
Female
Humans
Male
Medicine
Medicine & Public Health
Middle Aged
Receptor, Angiotensin, Type 1 - immunology
Rheumatology
Scleroderma, Systemic - blood
Scleroderma, Systemic - complications
Scleroderma, Systemic - diagnosis
Scleroderma, Systemic - immunology
Severity of Illness Index
Skin Ulcer - blood
Skin Ulcer - etiology
Skin Ulcer - immunology
SummonAdditionalLinks – databaseName: SpringerLink Journals (ICM)
  dbid: U2A
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fa9cwED_mBPFF1Pmj25QIPkwl0KZp2u6tiGMbzAfZF_ZW0jQnBWmH7fcf2V-8u_7SMRV86UuvScldks_lc3cBeB_aPLY6Q-kzp6UmxcoMyZbRxZ5MoMIk49zhi6_mdKPPr5KrOY-7X6LdF0pyXKnXZDcmkNj7NTI2TF8-gIcJue4cx7VRxUodpGZMDWbfRmb0WKjMPzVxdzO6hzDvsaPjpnPyFJ7MaFEUk3qfwY5vn8Oji5kP34Oboh0aadvvTTdGorfi7EzwqaqIBC1l_po8amG3Q0fj11QdRwyKo-Iy-iaLov8gSH6uq9oLPpAVU13nxomeuqNfbvpjwSd8okNhfylyEp65HcEVNND3E6ffv4DNyZfLz6dyvmVBujhVg6T9SUc1Jqgjr6qE_LHYVVWap0kd1UpXUYrOqjxVaBSthd6locGYnVtEo9HGL2G37Vr_GkSukfAXhpjrWsfWWoJXlQtVnSeEWiIXQLgMd-nmEuR8E8aPci2ePGqo5LAz1lCpA_i4fnI91d_4l_DhosNynop9ydep0y5NUCuAd-trmkTMjNjWd1uWYbpQE5wJ4NWk-7U3lXFNMmMC-LQYw2-N_-1X9v9L-gAeK4YLY0TQIewOP7f-DYGdoXo7GvctFmj1oQ
  priority: 102
  providerName: Springer Nature
Title Anti-angiotensin II type 1 receptor autoantibodies (AT1R-AAs) in patients with systemic sclerosis: lack of association with disease manifestations
URI https://link.springer.com/article/10.1007/s00296-016-3639-4
https://www.ncbi.nlm.nih.gov/pubmed/28004166
https://www.proquest.com/docview/1879362065
https://www.proquest.com/docview/1851694224
Volume 37
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ba9VAEF60BfFFrLdG27KCD15YTDabmy8Sy6mt0iKlB44vDbubXQlIcnRz_os_15lkk1qKfUkg2SRLZjIzO9_kG0JehbKIpcgtM7kWTIBgWW5Bl62ODaiAskmO_w6fnqXHS_Fllax8ws35ssrJJg6Guu405sjfY1dsMLbgMT-ufzHsGoXoqm-hcZdsI3UZanW2mhdcyH045FjASbMcNhOqGQ4kohzLb6OUxSmCodf90o1g8wZQOvifo4fkgQ8caTlKeofcMe0jcu_UQ-OPyZ-y7Rsm2x9NNxSlt_TkhGKClUYUrJpZw-Kayk3fwatsVIfFg_R1eXHpNopGl-esLN0bCld5olVHMUNLR6LnRlMHD4WJN-4DxZQf7SyVV5IdB3uwhyKlhjVuBPndE7I8WlwcHjPfdoHpOOM9A4clotomVkSGqwQWaLFWKiuypI5qLlSUWS15kXGbcjCORmdhamNc7VqbCivjp2Sr7VqzS2ghLARkNrSFqEUspYR4S-mQ10UCYUykAxJOL73SnpMcW2P8rGY25UFOFdahoZwqEZC38yXrkZDjtsF7kyQr_2266kqTAvJyPg1fFUIlsjXdBscgfiggvgnIs1ED5qfxHEnK0jQg7yaV-Ofm_5vK89un8oLc5xgwDDVBe2Sr_70x-xDu9Opg0OkDsl1-_v51AftPi7Nv53B0ycu_CHL_YQ
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ba9VAEB5qBe2LeG-06goKXlhMNpubIBLUco7t6YOcwnlq3Gx2JSDJ0eQg_hN_hb_RmdyqFPvWl7xkN1ky385-c8kMwBNXJb6SseUm1pJLFCyPLWLZat8gBHIbxPTv8OIonB3Lj6tgtQW_x39hKK1y1Imdoi5qTT7yV9QVG5Utnphv1984dY2i6OrYQqOHxYH5-QNNtubN_D3K96kQ-x-W72Z86CrAtR-JlqM-ll5hAys9I_IA7Q9f53mUREHhFULmXmS1EkkkbChw7xsduaH1yZizNpRW-fjcS3AZD16XjL1oNRl4VGux8-kgKeAxXsYoqtsVLRWU7uuF3A8p-PrvOXiG3J4JzHbn3f51uDYQVZb2yLoBW6a6CVcWQyj-FvxKq7bkqvpS1l0SfMXmc0YOXeYx1KJmjcY8U5u2RtGVeU3JiuxZujxpNjnzTj7xNG2eM5w1FHZtGHmEWV9YutSswZfiwsvmNSMXI6stU6dI6gcPwSVGJTysafqkguY2HF-IQO7AdlVXZhdYIi0SQOvaRBbSV0ohv8u1K4okQNrkaQfc8aNneqiBTq04vmZT9eZOThnlvZGcMunAi2nKui8Act7gvVGS2aALmuwUuQ48nm7jLqbQjKpMvaExFK-UyKccuNsjYHqbiKkoWhg68HKExF8P_99S7p2_lEdwdbZcHGaH86OD-7AjiKx0-Uh7sN1-35gHSLXa_GGHbwafL3pD_QHZMDhe
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ba9VAEB7qKRRfxLvRqisoeGFpstncBJFoe-ix9lBKC31qutnsSkCSo8lB_Cf-Fn-dM7mcKsW-9SUv2d0smW9nZ_abnQF47qrEVzK23MRacomC5bFFLFvtG4RAboOY7g7vz8PdY_npJDhZg9_jXRgKqxx1Yqeoi1rTGfkWVcVGZYs75pYdwiIOtqfvF984VZAipnUsp9FDZM_8_IHuW_Nuto2yfiHEdOfo4y4fKgxw7Uei5aibpVfYwErPiDxAX8TXeR4lUVB4hZC5F1mtRBIJGwrUA0ZHbmh9cuysDaVVPo57DdYj8oomsP5hZ35wuOIworC7o0xOFo_xMXKqbpfCVFDwrxdyPyQq9t9d8YKpe4Gm7Xa_6U24MZitLO1xdgvWTHUbNvYHYv4O_EqrtuSq-lLWXUh8xWYzRse7zGOoU80CXXumlm2NgizzmkIX2cv06LRZ5sw7PeRp2rxi2GtI89owOh9mfZrpUrMGP4oTL5u3jA4cWW2ZOsdV33igmhgl9LCm6UMMmrtwfCUiuQeTqq7MA2CJtGgOWtcmspC-UgqtvVy7okgCNKI87YA7_vRMDxnRqTDH12yVy7mTU0ZRcCSnTDrwetVl0acDuazx5ijJbNAMTXaOYweerV7jmiaiRlWmXlIbYi8lWlcO3O8RsPqaiClFWhg68GaExF-D_28qDy-fylPYwMWUfZ7N9x7BdUGWSxectAmT9vvSPEa7q82fDABncHbVa-oP4KI9-Q
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Anti-angiotensin+II+type+1+receptor+autoantibodies+%28AT%5Esub+1%5ER-AAs%29+in+patients+with+systemic+sclerosis%3A+lack+of+association+with+disease+manifestations&rft.jtitle=Rheumatology+international&rft.au=Ilgen%2C+Ufuk&rft.au=Yayla%2C+M%C3%BC%C3%A7teba+Enes&rft.au=D%C3%BCzg%C3%BCn%2C+Nursen&rft.date=2017-04-01&rft.pub=Springer+Nature+B.V&rft.issn=0172-8172&rft.eissn=1437-160X&rft.volume=37&rft.issue=4&rft.spage=593&rft_id=info:doi/10.1007%2Fs00296-016-3639-4&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=4321033171
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0172-8172&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0172-8172&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0172-8172&client=summon